$329.76 +0.52 (%) Biogen Idec Inc - NASDAQ

Sep. 22, 2014 | 04:00 PM

Partner Headlines

  1. Gilead's Zydelig Approved In EU; Imbruvica In Wings

    IBD | Sep. 19, 2014 | 12:17PM EST
  2. 2 Columbia Growth Funds Notch Impressive Three-Month Performance

    Benzinga | Sep. 18, 2014 | 10:52AM EST
  3. Nasdaq Falls Hard, But Apple Resilient On iPhone Orders

    IBD | Sep. 15, 2014 | 14:55PM EST
  4. Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers

    IBD | Sep. 13, 2014 | 08:02AM EST
  5. Why Nine of Fifteen Oil Majors Are Undervalued

    YCharts | Sep. 12, 2014 | 18:34PM EST
  6. Medivation Eyes Blockbuster As Cancer Drug Gets An OK

    IBD | Sep. 11, 2014 | 17:41PM EST
  7. Stocks Show Modest Losses; Biotechs Pressured Again

    IBD | Sep. 11, 2014 | 14:46PM EST
  8. Biogen Idec Inc Suddenly Struggling To Keep Up With The Biotech Joneses

    Benzinga | Sep. 11, 2014 | 08:17AM EST
  9. Biogen Reports PLEGRIDY Two-Year Data Confirms Maintenance of Efficacy, Safety in MS Patients

    Benzinga | Sep. 11, 2014 | 07:32AM EST
  10. Biogen Announces Five-Year Results from ENDORSE Phase 3 Study Show TECFIDERA Provides Strong, Sustained Efficacy for RRMS

    Benzinga | Sep. 11, 2014 | 07:31AM EST
  11. Stocks Turn Higher After Soft Start; U.S. Silica Jumps

    IBD | Sep. 10, 2014 | 13:25PM EST
  12. ReceptosMS Drug Yields More Good Data; Stock Jumps

    IBD | Sep. 10, 2014 | 11:58AM EST
  13. Steadier, Better: 35 Years Of Low-Volatility Stocks

    YCharts | Sep. 8, 2014 | 20:54PM EST
  14. Allianz's Analyst Likes Biogen, Celgene & Gilead

    Benzinga | Sep. 6, 2014 | 17:28PM EST
  15. Indexes Trim Losses But Remain Lower At Midday

    IBD | Sep. 5, 2014 | 12:04PM EST
  16. Biogen: Moving From Collaboration To Innovation

    IBD | Aug. 29, 2014 | 16:14PM EST
  17. Economic Data Fuel Another All-Time High For S&P 500

    IBD | Aug. 26, 2014 | 15:36PM EST
  18. Celgene, Gilead Lead Big Biotech Stock Movers

    IBD | Aug. 26, 2014 | 14:38PM EST
  19. Biogen, Celgene In Buy Range; LinkedIn Coming Back

    IBD | Aug. 25, 2014 | 18:43PM EST
  20. Stocks Hold Decent Gains; InterMune Deal Sparks Biotechs

    IBD | Aug. 25, 2014 | 14:54PM EST
  21. Majority Of IBD 50 Firms Strong On Sponsorship

    IBD | Aug. 22, 2014 | 18:37PM EST
  22. Biogen's buy rating reaffirmed

    IBD | Aug. 18, 2014 | 18:40PM EST
  23. UPDATE: Morgan Stanley Reiterates On Biogen Idec Following Plegridy Approval

    Benzinga | Aug. 18, 2014 | 07:50AM EST
  24. Perrigo Regains Some Lost Ground On Fiscal Q4 Beat

    IBD | Aug. 14, 2014 | 18:36PM EST
  25. Perrigo Q4 Beats Estimates, But Guidance Misses

    IBD | Aug. 14, 2014 | 11:02AM EST
  26. Tech, Health Care Lead Q2 Earnings Beats

    IBD | Aug. 11, 2014 | 13:12PM EST
  27. #PreMarket Primer: Friday, August 8: U.S. To Begin Airstrikes In Iraq

    Benzinga | Aug. 8, 2014 | 07:00AM EST
  28. Top 4 Stocks In The Biotechnology Industry With The Highest Revenue

    Benzinga | Aug. 7, 2014 | 04:24AM EST
  29. Why Investors Should Closely Watch Celgene

    Benzinga | Aug. 6, 2014 | 16:53PM EST
  30. Biotech Gets A Lift On Popular Drug, Strong Pipeline

    IBD | Aug. 1, 2014 | 19:13PM EST
  31. Ken Fisher's Top Increaes of the Second Quarter

    GuruFocus | Jul. 28, 2014 | 19:06PM EST
  32. Ken Fisher's Top Increases of the Second Quarter

    GuruFocus | Jul. 28, 2014 | 19:06PM EST
  33. Chipotle, Facebook Rally On Upside Earnings Surprise

    IBD | Jul. 25, 2014 | 18:36PM EST
  34. Celgene, Alexion Beat Estimates, But Biotechs Fall

    IBD | Jul. 24, 2014 | 17:07PM EST
  35. Celgene, Alexion Earnings Top Street, But Stocks Fall

    IBD | Jul. 24, 2014 | 11:39AM EST
  36. Biogen, Gilead Profits Soar

    IBD | Jul. 23, 2014 | 18:38PM EST
  37. Biogen, Gilead Crush Earnings Estimates On Hot Drugs

    IBD | Jul. 23, 2014 | 18:17PM EST
  38. S&P 500 Posts New High; Biotechs, Airlines, Builders Up

    IBD | Jul. 23, 2014 | 16:16PM EST
  39. IPO Stock Watch: Biotechs Are Half Of July Calendar

    IBD | Jul. 23, 2014 | 16:07PM EST
  40. Vertex Is Poised For An Earnings Breakout

    Benzinga | Jul. 23, 2014 | 15:56PM EST
  41. Pepsi Beats; Positive Phase 3 Breast Cancer Data Creates Potential Buyout Target

    Benzinga | Jul. 23, 2014 | 15:46PM EST
  42. S&P 500 Flirts With High; Breadth Missing On Nasdaq

    IBD | Jul. 23, 2014 | 15:14PM EST
  43. Intuitive Surgical Rises On Upbeat Earnings; Xilinx Shares Slip

    Benzinga | Jul. 23, 2014 | 14:19PM EST
  44. S&P 500 Aims At New High; Biotechs Gap Up In Fast Trade

    IBD | Jul. 23, 2014 | 13:29PM EST
  45. Biogen Trounces Q2 Estimates As Tecfidera Outperforms

    IBD | Jul. 23, 2014 | 11:56AM EST
  46. Apple, Microsoft Lead Nasdaq Higher; Dow Falters

    IBD | Jul. 23, 2014 | 11:56AM EST
  47. Markets Mixed; PepsiCo Q2 Earnings Beat Street View

    Benzinga | Jul. 23, 2014 | 11:19AM EST
  48. Stocks: Mixed Open, Mixed Trade; Delta, Broadcom, Biogen Buck Up

    IBD | Jul. 23, 2014 | 10:44AM EST
  49. Morning Market Movers

    Benzinga | Jul. 23, 2014 | 09:41AM EST
  50. UPDATE: Biogen Idec Posts Stronger-Than-Expected Q2 Results, Shares Surge

    Benzinga | Jul. 23, 2014 | 09:13AM EST
Trading Center